The study also showed that patients receiving a 240 mg dose saw a 14% reduction in visceral fat, a 5% reduction in total fat, ...
The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to ...
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, ...
Wave Life Sciences (WVE) plunged nearly 50% on Thursday to reach a 52-week low as analysts argued that updated results from an early-stage trial for its weight-loss drug WVE-007 missed their ...
On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results